These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 24679006)

  • 21. Diagnostic Approach for Double-Hit and Triple-Hit Lymphoma Based on Immunophenotypic and Cytogenetic Characteristics of Bone Marrow Specimens.
    Kim H; Kim HJ; Kim SH
    Ann Lab Med; 2020 Sep; 40(5):361-369. PubMed ID: 32311849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prognosis of
    Clipson A; Barrans S; Zeng N; Crouch S; Grigoropoulos NF; Liu H; Kocialkowski S; Wang M; Huang Y; Worrillow L; Goodlad J; Buxton J; Neat M; Fields P; Wilkins B; Grant JW; Wright P; Ei-Daly H; Follows GA; Roman E; Watkins AJ; Johnson PW; Jack A; Du MQ
    J Pathol Clin Res; 2015 Jul; 1(3):125-133. PubMed ID: 27347428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma.
    Rosenthal A; Younes A
    Blood Rev; 2017 Mar; 31(2):37-42. PubMed ID: 27717585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas: A Retrospective Cohort Study.
    Schiefer AI; Kornauth C; Simonitsch-Klupp I; Skrabs C; Masel EK; Streubel B; Vanura K; Walter K; Migschitz B; Stoiber D; Sexl V; Raderer M; Chott A; da Silva MG; Cabecadas J; Müllauer L; Jäger U; Porpaczy E
    Medicine (Baltimore); 2015 Dec; 94(52):e2388. PubMed ID: 26717387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations?
    Mationg-Kalaw E; Tan LH; Tay K; Lim ST; Tang T; Lee YY; Tan SY
    Histopathology; 2012 Dec; 61(6):1214-8. PubMed ID: 23171357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors.
    Li W; Gupta SK; Han W; Kundson RA; Nelson S; Knutson D; Greipp PT; Elsawa SF; Sotomayor EM; Gupta M
    J Hematol Oncol; 2019 Jul; 12(1):73. PubMed ID: 31288832
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma.
    Kramer MH; Hermans J; Wijburg E; Philippo K; Geelen E; van Krieken JH; de Jong D; Maartense E; Schuuring E; Kluin PM
    Blood; 1998 Nov; 92(9):3152-62. PubMed ID: 9787151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas.
    Sarkozy C; Traverse-Glehen A; Coiffier B
    Lancet Oncol; 2015 Nov; 16(15):e555-e567. PubMed ID: 26545844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Successful treatment with dose-adjusted EPOCH-R for triple-hit lymphoma having BCL2, BCL6 and MYC translocations].
    Hashimoto A; Fujimi A; Kanisawa Y; Nakajima C; Hayasaka N; Yamada S; Okuda T; Minami S; Matsumoto T; Shibata T; Hamaguchi K; Kamihara Y; Iwasaki S; Kato J
    Rinsho Ketsueki; 2015 Jul; 56(7):905-10. PubMed ID: 26256929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomas.
    Willenbacher E; Willenbacher W; Weger R; Dominik W; Manzl C; Brunner A
    Ann Hematol; 2020 Sep; 99(9):2125-2132. PubMed ID: 32613279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aggressive B-cell lymphomas with translocations involving BCL6 and MYC have distinct clinical-pathologic characteristics.
    Turakhia SK; Hill BT; Dufresne SD; Nakashima MO; Cotta CV
    Am J Clin Pathol; 2014 Sep; 142(3):339-46. PubMed ID: 25125624
    [TBL] [Abstract][Full Text] [Related]  

  • 32. B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas.
    Li S; Seegmiller AC; Lin P; Wang XJ; Miranda RN; Bhagavathi S; Medeiros LJ
    Mod Pathol; 2015 Feb; 28(2):208-17. PubMed ID: 25103070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B-cell lymphoma.
    Kawamoto K; Miyoshi H; Yoshida N; Nakamura N; Ohshima K; Sone H; Takizawa J
    Cancer Sci; 2016 Jun; 107(6):853-61. PubMed ID: 27027803
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
    Ye Q; Xu-Monette ZY; Tzankov A; Deng L; Wang X; Manyam GC; Visco C; Montes-Moreno S; Zhang L; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Piris MA; Winter JN; Medeiros LJ; Hu S; Young KH
    Oncotarget; 2016 Jan; 7(3):2401-16. PubMed ID: 26573234
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BCL2, BCL6, IGH, TP53, and MYC protein expression and gene rearrangements as prognostic markers in diffuse large B-cell lymphoma: a study of 44 Turkish patients.
    Akay OM; Aras BD; Isiksoy S; Toprak C; Mutlu FS; Artan S; Oner U; Gulbas Z
    Cancer Genet; 2014 Mar; 207(3):87-93. PubMed ID: 24674866
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutational landscape of high-grade B-cell lymphoma with
    Künstner A; Witte HM; Riedl J; Bernard V; Stölting S; Merz H; Olschewski V; Peter W; Ketzer J; Busch Y; Trojok P; Bubnoff NV; Busch H; Feller AC; Gebauer N
    Haematologica; 2022 Aug; 107(8):1850-1863. PubMed ID: 34788985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Malignant hematopoietic cell lines: in vitro models for double-hit B-cell lymphomas.
    Drexler HG; Eberth S; Nagel S; MacLeod RA
    Leuk Lymphoma; 2016 May; 57(5):1015-20. PubMed ID: 26727417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. "Triple hit" lymphomas: A retrospective cytology case series of an uncommon high grade B-cell malignancy with C-MYC, BCL-2 and BCL-6 rearrangements.
    Eldessouki T; Hanley K; Hamadeh F; Oshilaja OO; Sturgis CD
    Diagn Cytopathol; 2018 Sep; 46(9):807-811. PubMed ID: 30043475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas.
    Cinar M; Rosenfelt F; Rokhsar S; Lopategui J; Pillai R; Cervania M; Pao A; Cinar B; Alkan S
    Leuk Res; 2015 Jul; 39(7):730-8. PubMed ID: 25916698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Double-hit and triple-hit lymphomas arising from follicular lymphoma following acquisition of MYC: report of two cases and literature review.
    Xu X; Zhang L; Wang Y; Zhang Q; Zhang L; Sun B; Zhang Y
    Int J Clin Exp Pathol; 2013; 6(4):788-94. PubMed ID: 23573328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.